Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/aisy.202000070 http://scihub22266oqcxt.onion/10.1002/aisy.202000070 C7235485!7235485!32838299     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32838299&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32838299.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Adv+Intell+Syst 2020 ; 2 (5): � Nephropedia Template TP {{tp|p=32838299|t=2020. Addressing COVID?19 Drug Development with Artificial Intelligence |pdf=|usr=}}{{32838299}} gab.com Text Addressing COVID 19 Drug Development with Artificial Intelligence JO: Adv Intell Syst http://www.kidney.de/pget.php?&tw=1&pmid=32838299 #FOAvip The emergence of severe acute respiratory syndrome coronavirus 2 (SARS?CoV?2), the virus that led to the COVID?19 (Coronavirus Disease 2019) pandemic, has resulted in substantial overburdening of healthcare systems as well as an economic crisis on a global scale. This has in turn resulted in widespread efforts to identify suitable therapies to address this aggressive pathogen. Therapeutic antibody and vaccine development are being actively explored, and a phase I clinical trial of mRNA?1273 which is developed in collaboration between the National Institute of Allergy and Infectious Diseases and Moderna, Inc. is currently underway. Timelines for the broad deployment of a vaccine and antibody therapies have been estimated to be 12?18?months or longer. These are promising approaches that may lead to sustained efficacy in treating COVID?19. However, its emergence has also led to a large number of clinical trials evaluating drug combinations composed of repurposed therapies. As study results of these combinations continue to be evaluated, there is a need to move beyond traditional drug screening and repurposing by harnessing artificial intelligence (AI) to optimize combination therapy design. This may lead to the rapid identification of regimens that mediate unexpected and markedly enhanced treatment outcomes. Twit Text FOAVip Addressing COVID 19 Drug Development with Artificial Intelligence ????Adv Intell Syst http://www.kidney.de/pget.php?&tw=1&pmid=32838299 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32838299 #FOAvip English Wikipedia <ref>{{Cite pmid|32838299}}</ref> Addressing COVID?19 Drug Development with Artificial Intelligence #MMPMID32838299 Ho D Adv Intell Syst 2020[May]; 2 (5): � PMID32838299show ga The emergence of severe acute respiratory syndrome coronavirus 2 (SARS?CoV?2), the virus that led to the COVID?19 (Coronavirus Disease 2019) pandemic, has resulted in substantial overburdening of healthcare systems as well as an economic crisis on a global scale. This has in turn resulted in widespread efforts to identify suitable therapies to address this aggressive pathogen. Therapeutic antibody and vaccine development are being actively explored, and a phase I clinical trial of mRNA?1273 which is developed in collaboration between the National Institute of Allergy and Infectious Diseases and Moderna, Inc. is currently underway. Timelines for the broad deployment of a vaccine and antibody therapies have been estimated to be 12?18?months or longer. These are promising approaches that may lead to sustained efficacy in treating COVID?19. However, its emergence has also led to a large number of clinical trials evaluating drug combinations composed of repurposed therapies. As study results of these combinations continue to be evaluated, there is a need to move beyond traditional drug screening and repurposing by harnessing artificial intelligence (AI) to optimize combination therapy design. This may lead to the rapid identification of regimens that mediate unexpected and markedly enhanced treatment outcomes. �Addressing COVID?19 Drug Development with Artificial Intelligence (epmc).pdf DeepDyve Pubget Overpricing